Restoring mitochondrial dysfunction to address neurodegenerative and metabolic diseases

Explore the science

Press release

First 100 Patients Enrolled in Phase 3 Trial of ScandiBio Therapeutics AI-developed Drug for Alzheimer´s Disease

ScandiBio Therapeutics AB today announced that the first 100 patients have been recruited to the multi-centre, phase 3 human clinical trial evaluating the efficacy and safety of their pharmaceutical, Combined Metabolic Activator (CMA), in patients with Alzheimer’s disease (AD).

Full Press Release

Limitless Possibilities

AI-Driven Scientific Discovery leads to development of pharmaceutical drugs targeting metabolic diseases

Mitochondrial deficiency, characterized by a reduced number of mitochondria or impaired mitochondrial function, is a key factor in many modern health conditions, including neurodegenerative disorders and metabolic syndromes.

Learn More

The Company

What you need to know:

ScandiBio Therapeutics

A Stockholm-based company, is developing a pharmaceutical drugs that targets mitochondrial dysfunction.

Our Lead Product

Has recently entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer’s disease.

We are

Founded by scientists affiliated with KTH Royal Institute Technology (Stockholm), Karolinska Institutet (Stockholm), Sahlgrenska University hospital (Gothenburg) and King´s College (London).